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Abstract 
Background: The International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) has recently proposed 
nomenclature in order to harmonize ANA indirect immunofluorescence (IIF) pattern reporting. ICAP distinguishes 
competent‑level from expert‑level patterns. A survey was organized to evaluate reporting, familiarity, and considered 
clinical value of ANA IIF patterns.
Methods: Two surveys were distributed by European Autoimmunity Standardization Initiative (EASI) working groups, 
the International Consensus on ANA Patterns (ICAP) and UK NEQAS to laboratory professionals and clinicians.
Results: 438 laboratory professionals and 248 clinicians from 67 countries responded. Except for dense fine speck‑
led (DFS), the nuclear competent patterns were reported by > 85% of the laboratories. Except for rods and rings, the 
cytoplasmic competent patterns were reported by > 72% of laboratories.
Cytoplasmic IIF staining was considered ANA positive by 55% of clinicians and 62% of laboratory professionals, with 
geographical and expertise‑related differences.
Quantification of fluorescence intensity was considered clinically relevant for nuclear patterns, but less so for cytoplas‑
mic and mitotic patterns. Combining IIF with specific extractable nuclear antigens (ENA)/dsDNA antibody testing was 
considered most informative.
Of the nuclear competent patterns, the centromere and homogeneous pattern obtained the highest scores for clini‑
cal relevance and the DFS pattern the lowest. Of the cytoplasmic patterns, the reticular/mitochondria‑like pattern 
obtained the highest scores for clinical relevance and the polar/Golgi‑like and rods and rings patterns the lowest.
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Keymessages
We report on an international survey on Antinuclear 
Antibody (ANA) indirect immunofluorescence (IIF) pat-
tern reporting.
Both clinicians and laboratory professionals consider 
the major nuclear and cytoplasmic  IIF patterns as clini-
cally important.
There is no unanimity on reporting cytoplasmic pat-
terns as ANA IIF positive.
Background
Indirect immunofluorescence (IIF) on HEp-2 cells is 
commonly used to screen for antinuclear antibodies 
(ANA). ANA are helpful for the diagnosis of ANA-asso-
ciated rheumatic diseases (AARD) [1, 2]. In the recent 
classification criteria for systemic lupus erythematosus, 
the presence of ANA is an entry criterion [3]. Besides, 
ANA are a prognostic marker for uveitis in children with 
juvenile idiopathic arthritis [4] and ANA positivity and 
titers are included in the internationally-accepted, sim-
plified criteria for the diagnosis of autoimmune hepati-
tis [5–7]. Finally, some ANA patterns can point towards 
specific diseases such as the reticular/mitochondria-like 
pattern in primary biliary cholangitis and the centromere 
pattern in systemic sclerosis [8–10]. Guidelines for ANA 
detection by IIF recommend to report ANA titer and pat-
tern [11, 12]. The higher the antibody level, the higher the 
likelihood for disease [13–15]. In addition, the combina-
tion of the antibody level and the antibody pattern can 
also provide helpful information [16].
The International Consensus on ANA Patterns 
(ICAP), a working group of the Autoantibody Stand-
ardization Committee (ASC) [17], has recently pro-
posed an ordered nomenclature in order to harmonize 
the names and descriptions of distinct HEp-2 IIF pat-
tern [18]. At the time of the survey (2019), 30 anti-
cell (AC) patterns compose the ICAP classification 
tree [19]. The morphological description and exam-
ples of the AC patterns are accessible (in several lan-
guages) at the ICAP website (www.anapa ttern s.org 
and [20]). ICAP distinguishes patterns that should be 
readily recognized (competent-level) from patterns 
that require more experience (expert-level). This dis-
tinction is not only based on the fact that the pattern 
is easily recognizable, but also on its clinical relevance 
[17]. According to ICAP, the following AC patterns are 
competent-level: nuclear homogenous, speckled, dense 
fine speckled (DFS), centromere, nucleolar and discrete 
dots and cytoplasmic fibrillary, speckled, reticular/
mitochondria-like, polar/Golgi-like and rods and rings. 
ICAP acknowledges that the distinction is a temporary 
status and is subject to feedback and commentaries 
from the international community [17].
In order to evaluate to which extent clinical labora-
tories and clinicians adhere to the ICAP recommen-
dations and appreciate the clinical value of the IIF 
patterns, a survey on ANA IIF pattern reporting and 
interpretation was organized. The results of such sur-
veys should guide further harmonization.
Methods
The Belgian European Autoimmunity Standardization 
Initiative (EASI) working group prepared two struc-
tured survey forms, one addressed to laboratory pro-
fessionals, reporting ANA IIF test results, and one to 
clinicians, requesting ANA IIF tests and interpreting 
the ANA IIF result report. Both survey forms (available 
as Additional file  1 and Additional file  2) interrogated 
reporting, familiarity and clinical significance of ANA 
IIF patterns. During a 2 year period (06/2017–05/2019), 
the survey forms were distributed to laboratory pro-
fessionals and rheumatologists by the EASI working 
groups. Besides, the survey forms were also distributed 
through UK NEQAS and ICAP. The specialty of the cli-
nicians that participated through ICAP is not known.
Globally, the surveys forms were distributed in the 
following formats:
1. open, web-based survey (Austria, Spain, Italy, Croa-
tia, Sweden, UK, Switzerland, Portugal, Estonia, 
Greece)
2. closed survey (Belgium, Finland, the Netherlands, 
laboratories that are subscribed to ICAP with exclu-
sion of the countries mentioned above as they were 
addressed through EASI)
Statistical analysis (chi-squared test relative propor-
tion) was performed in MEDCALC (software version 
17.1., Ostend, Belgium). A p value < 0.05 was consid-
ered as statistically significant.
Conclusion: This survey confirms that the major nuclear and cytoplasmic ANA IIF patterns are considered clinically 
important. There is no unanimity on classifying DFS, rods and rings and polar/Golgi‑like as a competent pattern and 
on reporting cytoplasmic patterns as ANA IIF positive.
Keywords: Antinuclear antibodies, ANA patterns, Indirect immunofluorescence, ICAP
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Results
Characteristics of the participating laboratories 
and clinicians
Four hundred thirty-eight laboratory professionals 
and 248 clinicians (183 or 74% rheumatologists, for the 
other clinicians, specialty is not known) from 67 differ-
ent countries worldwide responded to the surveys, of 
whom 358 (82%) and 84 (34%), respectively, completed 
the whole survey. Since the survey was also distributed 
through an open, web-based format we were unable to 
accurately estimate the response rate. Table  1 shows 
the geographic distribution of the respondents. Most of 
the respondents were from Europe (259/438 or 59% of 
laboratory professionals and 206/248 or 83% of the cli-
nicians). Fifty percent (220/438) of the laboratory pro-
fessionals that responded considered their laboratory as 
expert-level (i.e. recognize patterns that require more 
expertise) and 54% (135/248) of the clinicians worked in 
a tertiary hospital.
Reporting of ANA IIF patterns
Table  2 represents an overview of (i) the frequency of 
reporting of the various AC patterns, (ii) the estimation 
whether a pattern should be classified as competent, and 
(iii) the clinical relevance of the various AC patterns. 
For the clinical relevance score, 1 is the lowest and 5 the 
highest score.
For each question, the results per pattern, are pre-
sented as percentages of the total laboratory (competent 
and expert reported separately) and clinician respond-
ents. The competent patterns are highlighted in bold. The 
reported range represents the minimum and maximum 
number of responders to the specific questions posed.
The competent-level patterns centromere (AC-3), 
homogeneous (AC-1), speckled (AC-2,4,5) and nucleo-
lar (AC-8,9,10) patterns were used in ANA IIF test result 
reporting by > 90% of competent-level and expert-level 
laboratories (Table 2). The nuclear dot patterns (AC-6,7) 
were reported by 85% of the laboratories and the DFS 
pattern (AC-2) by 62% of the laboratories. Clinicians 
reported comparable (or somewhat lower) frequencies of 
being acquainted with those patterns (Table 2).
Cytoplasmic AC patterns were less frequently used in 
ANA IIF test result reporting than nuclear AC patterns. 
Among the competent cytoplasmic patterns (fibrillar 
(AC-15,16,17), speckled (AC-18,19,20), reticular/ mito-
chondria-like (AC-21), polar/Golgi-like (AC-22), rods 
and rings (AC-23), the rods and rings pattern (AC-23) 
was the pattern that was least used (63% of the laborato-
ries) (Table 2).
The competent-level DFS pattern (AC-2) and rods and 
rings pattern (AC-23) were significantly (p < 0.0001) more 
used by expert-level laboratories than by competent-level 
laboratories (76% versus 48% for DFS and 73% versus 
53% for rods and rings). Moreover, the DFS pattern was 
less reported by laboratories in North-America (44%) 
and Europe (57%) than by laboratories in the other con-
tinents (Table 3).
Table 1 Geographic distribution of  the  respondents with  information on  laboratories and  clinicians showing (i) 
the  geographic distribution of  the  respondents, (ii) the  classification of  laboratories as  competent or  expert and  (iii) 
the  clinical setting of  the  clinicians (N.a.: not  applicable; Total completed: number of  respondents that  completed 
the whole survey)
Countries of origin of laboratory experts: Africa: Algeria, Egypt, Morocco, Saudi-Arabia, South-Africa, Tunisia; Asia: Azerbaijan, China, Hong Kong, India, Indonesia, Iran, 
Israel, Korea, Lebanon, Malaysia, Pakistan, Taiwan, Thailand, United Arab Emirates; Europe: Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Kazakhstan, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, 
Spain, Sweden, Switzerland, Turkey, United Kingdom; North-America: Canada, Guatemala, Mexico, Nicaragua, Panama, United States of America; South-America: 
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Peru, Uruguay, Venezuela
Countries of origin of clinicians: Asia: China, India, Japan, Korea, Malaysia, Taiwan; Europe: Austria, Belgium, Croatia, Cyprus, Estonia, Finland, Greece, Hungary, Italy, 
Lithuania, Netherlands, Norway, Poland, Serbia, Slovakia, Spain, Sweden, Turkey, United Kingdom; North-America: Canada, Mexico, Dominican Republic, United States 
of America; South-America: Argentina, Brazil, Chile, Peru
Continent Laboratory professionals Clinicians
Competent Expert n.a Total Primary setting Secundary setting Tertiary setting n.a Total
Africa 6 4 10
Asia 33 27 1 61 2 11 1 14
Australia 1 5 6 2 2
Europe 121 134 4 259 49 47 107 3 206
North‑America 17 19 1 37 3 1 5 1 10
South‑America 30 31 3 64 1 4 10 15
(Not assigned) 1 1 1 1
Total 209 (47.7%) 220 (50.2%) 9 438 54 (21.8%) 54 (21.8%) 135 (54.4%) 5 248
Total completed 166 186 6 358 11 11 60 2 84
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Distinction between competent and expert patterns
Laboratory professionals were also interrogated 
whether they would classify a pattern as competent 
or expert-level. For most of the nuclear patterns there 
was a good agreement (84–89%) between the ICAP 
classification and the provided responses, except for 
the DFS pattern. Only 50% of the respondents would 
classify this pattern as competent (Table  2). Of inter-
est, 72% of the respondents considered the nuclear 
envelope pattern a competent pattern rather than an 
expert pattern.
For the cytoplasmic patterns considered competent-
level by ICAP, 71%—74% of the respondents consider 
the fibrillary, speckled and reticular/mitochondria-
like pattern a competent pattern, 65% considered the 
polar/Golgi-like pattern a competent pattern and 57% 
considered the rods and rings pattern a competent pat-
tern (Table 2).
Are cytoplasmic patterns considered ANA positive?
Sixty-one percent of the clinicians (n = 105) and 54% of 
the laboratory professionals (n = 346) considered cyto-
plasmic HEp-2 cell IIF staining as ANA IIF positive. 
There were more expert-level laboratory profession-
als (61%) than competent-level laboratory professionals 
(46%) that considered cytoplasmic patterns as ANA posi-
tive (p = 0.0062). The fraction of laboratory professionals 
that considered cytoplasmic ANA patterns as ANA posi-
tive was higher in non-European countries (63%) than in 
European countries (48%) (p = 0.0075) (Table  4a). How-
ever, within Europe, differences between countries were 
observed. In Austria (15%; n = 2/13), the Netherlands 
(12%; n = 3/25), Sweden (13%; n = 1/8), Switzerland (29%; 
Table 3 Demographic differences  in  reporting the  dense fine speckled (AC-2) and  the  rods and  rings pattern (AC-23), 
with results shown and presented as percentage (%) of the total responders % per geographic continent
a p = 0.1217 versus North-America and p = 0.3115 versus Europe
b p = 0.0009 versus North-America and p = 0.0030 versus Europe
c p = 0.0813 versus North-America and p = 0.1985 versus Europe
d p = 0.0022 versus North-America and p = 0.0084 versus Europe
N.a. not applicable
a) Dense fine speckled (AC-2) 
Laboratory professionals Clinicians
Total Competent Expert
Continent n Reporting (%) n Reporting (%) n Reporting (%) n Reporting (%)
Africa 8 6 (75.0%)a 5 3 (60.0%) 3 3 (100%) 0 n.a
Asia 59 46 (78.0%)b 33 22 (66.7%) 26 24 (92.3%) 9 5 (55.6%)
Australia 6 5 (83.3%)c 1 0 (0.0%) 5 5 (100%) 2 1 (50.0%)
Europe 251 143 (57.0%) 118 48 (40.7%) 133 95 (71.4%) 143 78 (54.5%)
North Amercia 36 16 (44.4%) 17 7 (41.2%) 19 9 (47.4%) 7 2 (28.6%)
South America 61 46 (75.4%)d 30 18 (60.0%) 31 28 (90.3%) 11 8 (72.7%)
Total 421 262 (62.2%) 204 98 (48.0%) 217 164 (75.6%) 172 94 (54.7%)
b) Rods and rings (AC-23)
Laboratory Clinicians
Total Competent Expert
Continent n Reporting (%) n Reporting (%) n Reporting (%) n Reporting (%)
Africa 10 8 (80.0%) 6 5 (83.3%) 4 3 (75.0%) 0 n.a
Asia 59 45 (76.3%) 33 23 (69.7%) 26 22 (84.6%) 9 3 (33.3%)
Australia 5 1 (20.0%) 1 0 (0.0%) 4 1 (25.0%) 2 0 (0.0%)
Europe 247 149 (60.3%) 116 55 (47.4%) 131 94 (71.8%) 140 33 (23.6%)
North Amercia 36 22 (61.1%) 17 8 (47.1%) 19 14 (73.7%) 7 2 (28.6%)
South America 59 36 (61.0%) 30 15 (50.0%) 29 21 (72.4%) 11 3 (27.3%)
Total 416 261 (62.7%) 203 106 (52.2%) 213 155 (72.8%) 169 41 (24.3%)
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n = 2/7), Turkey (20%; n = 1/5) and the United King-
dom (22%; n = 2/9), cytoplasmic ANA IIF patterns were 
considered ANA positive by < 30% of laboratory profes-
sionals, while in Belgium (65%; n = 22/34), France (57%; 
n = 4/7), Italy (61%; n = 11/18), Portugal (78%; n = 18/23) 
and Spain (67%; n = 14/21), cytoplasmic patterns are con-
sidered ANA positive by > 60% of the laboratory profes-
sionals (Table 4b).
Table 4 Geographic variation in considering cytoplasmic ANA IIF patterns as ANA positive
a n = 6 laboratories reported expertise level ‘not applicable’ and n = 1 no country
a) The results are presented as absolute numbers and in percentage (%) of the responders per geographic continent
Total Competent Expert
Continent n Reporting (%) n Reporting (%) n Reporting (%)
Africa 5 3 (60.0%) 4 2 (50.0%) 1 1 (100.0%)
Asia 48 32 (66.7%) 26 16 (61.5%) 22 16 (72.7%)
Australia 5 0 (0.0%) 1 0 (0.0%) 4 0 (0.0%)
Europe 211 102 (48.3%) 98 40 (40.8%) 113 62 (54.9%)
North Amercia 28 18 (64.3%) 12 6 (50.0%) 16 12 (75%)
South America 49 32 (65.3%) 23 12 (52.2%) 26 20 (76.9%)
Total 346a 187 (54.1%) 164 76 (46.3%) 182 111 (61.0%)
b) The results are presented as percentage (%) of the total responders per participating European country
Total Competent Expert
Country n ANA positive (%) n ANA positive (%) n ANA positive (%)
Austria 13 2 (15.4%) 3 0 (0.0%) 10 2 (20.0%)
Belgium 34 22 (64.7%) 25 13 (52%) 9 9 (100.0%)
Bosnia and Herzegovina 1 1 (100.0%) 1 1 (100.0%) n.a n.a
Bulgaria 1 0 (0.0%) n.a n.a 1 0 (0.0%)
Croatia 6 3 (50.0%) 2 1 (50.0%) 4 2 (50.0%)
Czech Republic 1 0 (0.0%) 1 0 (0.0%) n.a n.a
Denmark 1 0 (0.0%) 1 0 (0.0%) n.a n.a
Estonia 5 5 (100.0%) 2 2 (100.0%) 3 3 (100.0%)
Finland 4 2 (50.0%) 2 1 (50.0%) 2 1 (50.0%)
France 7 4 (57.1%) 4 2 (50.0%) 3 2 (66.7%)
Germany 1 0 (0.0%) n.a n.a 1 0 (0.0%)
Greece 7 3 (42.9%) 2 1 (50.0%) 5 2 (40.0%)
Hungary 3 0 (0.0%) n.a n.a 3 0 (0.0%)
Italy 18 11 (61.1%) 5 2 (40.0%) 13 9 (69.2%)
Kazakhstan 2 2 (100.0%) 2 2 (100.0%) n.a n.a
Malta 1 1 (100.0%) n.a n.a 1 1 (100%)
Netherlands 25 3 (12.0%) 20 2 (10.0%) 5 1 (20.0%)
Norway 1 0 (0.0%) n.a n.a 1 0 (0.0%)
Poland 3 2 (66.7%) n.a n.a 3 2 (66.7%)
Portugal 23 18 (78.3%) 8 6 (75.0%) 15 12 (80.0%)
Romania 2 2 (100.0%) n.a n.a 2 2 (100.0%)
Serbia 1 0 (0.0%) 1 0 (0.0%) n.a n.a
Slovakia 1 1 (100.0%) n.a n.a 1 1 (100.0%)
Spain 21 14 (66.7%) 8 5 (62.5%) 13 9 (69.2%)
Sweden 8 1 (12.5%) 1 0 (0.0%) 7 1 (14.3%)
Switzerland 7 2 (28.6%) n.a n.a 7 2 (28.6%)
Turkey 5 1 (20.0%) 2 1 (50.0%) 3 0 (0.0%)
United Kingdom 9 2 (22.2%) 9 2 (22.2%) 0 0 (0.0%)
Total 211 102 (48.3%) 99 41 (41.4%) 112 61 (54.5%)
Page 8 of 12Van Hoovels et al. Autoimmun Highlights           (2020) 11:17 
Sub-specification of patterns
Less than half of the clinicians and laboratory profes-
sionals found it important to sub-specify (i) nucleo-
lar patterns into homogeneous, clumpy and speckled 
(AC-8,9,10) (respectively 45% and 34%), (ii) cytoplasmic 
fibrillary patterns into linear, filamentous and segmental 
(AC-15,16,17) (respectively 28% and 42%) and (iii) cyto-
plasmic speckled patterns into discrete dots, dense fine 
speckled and fine speckled (AC-18,19,20) (respectively 
42% and 53%). Seventy-one percent of the clinicians and 
86% of the laboratory professionals found it important to 
report the reticular/mitochondria-like cytoplasmic pat-
tern (AC-21). Sixty-two percent of the laboratory pro-
fessionals distinguished multiple nuclear dots from few 
nuclear dots (AC-6,7) (data not shown).
The most used sub-specifications in ANA IIF result 
reports are nuclear fine speckled AC-4 (63%), nuclear 
coarse speckled AC-5 (65%), multiple nuclear dots AC-6 
(74%) and few nuclear dots AC-7 (69%). These sub-spec-
ifications are significantly more reported by expert-level 
than by competent-level laboratories (p < 0.0001 for all 
sub-patterns). However, clinicians are not aware of such 
ANA IIF sub-specification and do not consider them 
clinically relevant (Table 2).
Confirmation of IIF by specific tests
There was no difference between competent-level and 
expert-level laboratories regarding follow-up testing for 
antibodies to extractable nuclear antigens (ENA) and to 
dsDNA in case of a positive ANA IIF test. A geographi-
cal difference, however, was observed (Additional file  3. 
Table  S5). Forty-one percent of European laborato-
ries, but only 13% of North American and 10% of South 
American laboratories, systematically performed follow-
up testing for anti-ENA antibodies and to dsDNA in case 
of a positive ANA IIF test or on clinical indication when 
ANA IIF is negative. Forty-seven percent of the North-
American laboratories and 44% of the South-American 
ones, but only 16% of the European laboratories only per-
formed confirmation testing when the tests were specifi-
cally requested (Additional file 3. Table S5).
The majority of competent (72%; n = 165) and expert 
laboratories (79%; n = 179) review their ANA IIF results 
after ENA/dsDNA confirmation testing, but only a 
minority would change the results (respectively 8% and 
10%) or add a comment if clinically relevant (respectively 
36 and 46%).
Interpretation and clinical significance of ANA IIF patterns
Both clinicians (82%; n = 246) and laboratory profession-
als (81%; n = 352) considered the combination of an ANA 
IIF test result with a corresponding specific anti-ENA 
or anti-dsDNA test result as the most clinically relevant 
information.
The quantification of the nuclear ANA IIF fluorescence 
intensity was found clinically relevant by 79% of labora-
tory professionals and by 74% of clinicians (Additional 
file 4. Table S6). Thirty-three percent of laboratory pro-
fessionals and 22% of clinicians reported that one should 
not titrate cytoplasmic patterns. Forty-three percent of 
laboratory professionals and 33% of clinicians reported 
that mitotic patterns should not be titrated (Additional 
file 4. Table S6).
Fifty-four percent of the clinicians (n = 107) reported 
that they would take medical decisions based on ANA 
IIF titer, whereas 87% of the clinicians reported that they 
would take medical decision based on results of specific 
testing for anti-ENA or anti-dsDNA.
Clinicians and laboratory professionals were also inter-
rogated on how they appraise the clinical relevance of 
the various ANA patterns. Overall, clinicians scored 
the clinical relevance of the various patterns lower than 
laboratory professionals (Table  2). The highest scores 
for clinical relevance were obtained for the centromere 
(AC-3) pattern and the homogeneous (AC-1) pattern. 
Ninety-three percent of the laboratory professionals and 
84% of the clinicians scored the clinical relevance of the 
centromere pattern high, and 90.2% of the laboratory 
professionals and 70.6% of the clinicians scored the clini-
cal relevance of the homogeneous pattern high. Seventy-
seven to 80% of the laboratory professionals and 61–64% 
of the clinicians scored the clinical relevance of the 
nuclear speckled pattern (AC-2,4,5) and nucleolar pat-
tern (AC-8,9,10) high. In contrast, only 41% of laboratory 
professionals and 35% of clinicians scored the clinical rel-
evance of the DFS pattern (AC-2) high.
Of the cytoplasmic patterns, the reticular/mitochon-
dria-like pattern (AC-21) obtained the highest score for 
clinical relevance by laboratory professionals. The other 
competent cytoplasmic patterns received lower scores, 
with the lowest scores for polar/Golgi-like (AC-22) and 
rods and rings (AC-23).
The mitotic patterns obtained low scores for clinical 
relevance overall with ≤ 30% of the clinicians and labo-
ratory professionals scoring these patterns as clinically 
relevant.
Discussion
In the current paper, we present the results of a recent 
international survey on the reporting and interpretation 
of ANA IIF results in current daily practice. The results 
revealed concordances but also discordances with the 
recommendations posed by ICAP [18].
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The survey confirmed that there is no consensus on 
whether anti-cytoplasmic antibodies should be consid-
ered ANA IIF positive or negative [21, 22]. Even within 
Europe, there are divergences between countries, as the 
geographic block represented by Portugal, Spain, Italy, 
France and Belgium tend to report exclusive cytoplasmic 
reactivity as a positive test, whereas countries out of this 
axis only report nuclear reactivity as a positive test. ANA 
is the common clinical and laboratory term used for 
more than 50 years. The term is maintained for histori-
cal reasons as well as for laboratory coding and invoic-
ing. However, the name ‘antinuclear’ for the HEp-2 cell 
IIF test does not take into consideration that autoan-
tibodies to cell compartments other than the nucleus 
(i.e. cytoplasm, mitotic) are also detected and that these 
antibodies may be clinically relevant [10]. Therefore, the 
ICAP executive board, already in their first report, advo-
cates that in situations where there is a clear cytoplasmic 
or mitotic apparatus reactivity, these results need to be 
reported to the clinician. However, even within ICAP, the 
discussion on whether those patterns should be regarded 
as ANA IIF positive or negative has not reached consen-
sus [10, 17, 23]. Being aware that the term ‘Antinuclear 
antibody (ANA) test’ is inappropriate, the use of the sug-
gested alternative name, HEp-2 IIF test [10], will foster 
harmonization of reporting ANA IIF results.
The familiarity with ANA IIF patterns is mainly clear 
for the nuclear competent patterns (with the exception 
of DFS) and the cytoplasmic reticular/mitochondria-like 
antibody (AC-21) pattern, findings which are in concord-
ance to the results of a similar recent survey performed 
by the American association of Medical Laboratory 
Immunologists [24]. Clinicians were less familiar with 
the cytoplasmic reticular pattern than laboratory profes-
sionals, which might be related to the fact that the survey 
was mainly directed to rheumatologists (and not hepato-
gastroenterologists). Overall, cytoplasmic and mitotic 
patterns are less reported by laboratories than nuclear 
patterns. The integration of computer-aided immunoflu-
orescence microscopy could further improve the famili-
arity and consistency in pattern assignments [25, 26], 
although currently the existing systems are able to recog-
nize only a small fraction of patterns.
The survey shows that not all laboratories report the 
DFS pattern and the rods and ring pattern and that not 
all expert-level laboratory professionals are convinced 
that these two patterns should be classified as competent.
The DFS pattern (AC-2) can vary depending on the 
manufacturer of the HEp-2 cell substrates [27, 28] and its 
correct identification can be challenging, resulting in a 
high frequency of cases misclassified as DFS pattern [28, 
29]. Furthermore, the assumed clinical relevance of the 
DFS pattern to exclude AARD only holds if the specificity 
is confirmed and if it is monospecific for DFS70 [10, 27, 
30]. The inclusion of anti-DFS70 antibody testing in a 
diagnostic algorithm or reflex testing is currently under 
discussion [31, 32]. It has been proposed to better define 
the DFS AC-2 pattern in the ICAP classification algo-
rithm including a new pattern called ‘pseudo-DFS’ refer-
ring to the nuclear speckled pattern with clear staining 
of the metaphase plate, but without the typical features 
of the DFS (AC-2) pattern (i.e. a more homogeneous dis-
tribution and more uniform brightness of the nuclear 
speckles than in the typical DFS pattern). Distinguish-
ing this pattern from the classical DFS pattern would 
be important to increase the accuracy in the interpreta-
tion of the ANA IIF test [33]. The recent availability of 
a reference serum with mono-reactivity to DFS70 by the 
Autoantibody Standardization Committee of the Interna-
tional Union of Immunology Societies (www.autoa b.org) 
should help laboratories across the world to improve the 
ability in recognizing the DFS (AC-2) pattern [34].
In contrast to the DFS pattern, the rods and rings (AC-
23) pattern is easily recognizable and there is a defined 
clinical association (Hepatitis C virus infection under 
treatment with α-interferon and ribavirin) [10]. How-
ever, as mentioned in the ICAP nomenclature tree (www.
anapa ttern s.org), the AC-23 ANA IIF pattern is only 
detectable in selected HEp-2 cell slides. Thus, depending 
on the slide source (i.e. manufacturer) used, labs will be 
able or unable to report this pattern. This likely explains 
in part the relatively low recognition rate of this pattern 
even in expert laboratories.
Overall, the patterns that are most frequently reported 
are the patterns that are considered to have the high-
est clinical relevance, with some exceptions such as the 
centrosome, Golgi and spindle fiber patterns, which are 
reported by circa 80% of the laboratories despite not 
having peculiar clinical associations. In addition, the 
DFS pattern is reported in less than 50% of laboratories. 
Considering that this pattern includes the staining of the 
metaphase plate, the DFS pattern can be misclassified as 
nuclear homogeneous pattern (AC-1), which has com-
pletely different immunological and clinical implications.
In daily routine practice, sub-specifying nucleolar (AC-
8,9,10) patterns, cytoplasmic fibrillar patterns and cyto-
plasmic speckled patterns is infrequently performed, 
even among experts. However, clinicians do not consider 
such sub-classification clinically relevant (Table 2).
The highest scores for clinical relevance were obtained 
for the centromere (AC-3) and homogeneous (AC-1) pat-
tern, followed by the nuclear speckled (AC-2,4,5) and 
cytoplasmic reticular (AC-21) patterns. Especially the 
centromere pattern is associated with a specific disease 
(limited systemic sclerosis, primary biliary cholangitis 
and Sjögren’s syndrome) [16]. It is the only pattern that 
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has an almost absolute association with a restrict set of 
autoantibody specificities (anti-CENP-B and/or anti-
CENP-A). For all other patterns, follow-up testing to 
identify the target antigen is mandatory, and the pattern 
can help to guide such follow-up testing [10].
The clinical significance of the cytoplasmic patterns 
as a whole was considered lower compared to nuclear 
patterns. Even cytoplasmic patterns such as the (dense) 
fine speckled patterns that are associated with clinically 
relevant antibodies such as the anti-synthetase antibod-
ies, anti-SRP and anti-Rib-P are not widely recognized as 
clinically relevant patterns. This perception clearly indi-
cates the need for implementing education programs in 
order to increase the awareness of such associations and 
improve the interpretation and optimal use of the ANA 
IIF test. The polar/Golgi-like pattern is considered a 
competent pattern. It is easily recognizable but its clinical 
association with a disease is limited [10, 35–37].
The quantification of the ANA IIF fluorescence inten-
sity was found clinically relevant for the nuclear ANA IIF 
patterns by a substantial fraction of clinicians (74%) and 
laboratory experts (79%). The importance of the autoan-
tibody titer (level) is recognized by guidelines and rec-
ommendations [1, 3, 11, 12]. Recent studies showed that 
the likelihood for AARD increases with increasing ANA 
IIF fluorescence intensity [13–15]. However, important 
variation in the detection and titration of ANAs has been 
reported with manual and automated methods [38–41].
Clinicians are aware of the differences between labora-
tories for both ANA IIF and specific ENA/dsDNA test-
ing. A low percentage of clinicians take medical decisions 
based on the ANA IIF titer (54%).
Clinicians and laboratory professionals considered that 
combined information on HEp-2 ANA and specific tests 
for anti-ENA and anti-dsDNA antibodies is most inform-
ative. This is in line with recent studies that showed that 
combining an immunoassay with ANA IIF adds value if 
the results of both tests are correctly judged in the con-
text of the clinical manifestations of the patient [42, 43]. 
Furthermore, combining IIF with a solid-phase assay 
can assist in patient stratification, especially in case of a 
low-positive ANA IIF titer [42, 44, 45]. ICAP promotes 
to integrate the ANA IIF titer and pattern with advice for 
follow-up testing, taking into account the clinical presen-
tation of the patient [10, 46].
Conclusions
In conclusion, this international survey confirms that 
the major nuclear (homogenous, speckled, centromere, 
nucleolar and dots) and cytoplasmic (reticular) patterns 
are considered clinically important. It also supports the 
ICAP classification in competent and expert patterns 
for the majority of the competent patterns, but there 
is no unanimity on classifying DFS, rods and rings and 
polar/Golgi-like as a competent pattern. Compared to 
nuclear patterns, cytoplasmic patterns are less reported 
and their clinical relevance is considered lower than 
the clinical relevance of nuclear patterns. Combining 
IIF with testing for specific antibodies is considered to 
be most informative. There is no unanimity among the 
respondents regarding the question whether a cytoplas-
mic pattern is ANA IIF positive.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1331 7‑020‑00139 ‑9.
Additional file 1. International EASI questionnaire ANA IIF patterns for 
Clinicians.
Additional file 2. International EASI questionnaire ANA IIF patterns for 
laboratory professionals.
Additional file 3. Table S5. Demographic differences in confirming ANA 
IIF results with specific tests for anti‑ENA and anti‑dsDNA.
Additional file 4. Table S6. Overview of the fraction of respondents 
(laboratory professionals or clinicians) that considered it important to 
report the fluorescence intensity of nuclear, cytoplasmic or mitotic ANA 
IIF patterns.
Abbreviations
AARD: Antinuclear antibody associated rheumatic diseases; AC: Anti‑cell; ANA: 
Antinuclear antibody; ASC: Autoantibody Standardization Committee; ICAP: 
The International Consensus on Antinuclear Antibody Patterns; IIF: Indirect 
immunofluorescence; EASI: European Autoimmunity Standardization Initiative; 
DFS: Dense fine speckled; ENA: Extractable nuclear antigens.
Acknowledgements
We truly thank all laboratory professionals and clinicians that participated to 
the surveys.
Authors’ contributions
LVH, SB, SS and XB designed the study. SB distributed the survey among the 
participating expert organizations. The distribution among local members of 
the (international) organizations was performed by LA, DB, EKLC, JD, WdMC, 
CE, IH, MH, AK, LK, MLH, DP, AR, MJRdS and MV. LVH and XB drafted the 
manuscript. All authors read the manuscript, gave valuable comments, edited 
the manuscript and agreed upon the final submission. All authors read and 
approved the final manuscript.
Funding
Not applicable.
Availability of data and materials
The datasets used and analyzed during the current study are available from 
the corresponding author on reasonable request.





The authors declare that the research was conducted in the absence of any 
commercial or financial relationships that could be construed as a potential 
competing interest.
Page 11 of 12Van Hoovels et al. Autoimmun Highlights           (2020) 11:17  
Author details
1 Department of Laboratory Medicine, OLV Hospital, Aalst, Belgium. 2 Depart‑
ment of Microbiology and Immunology, KU Leuven, Leuven, Belgium. 
3 Sciensano (Formerly Scientific Institute of Public Health), Brussels, Belgium. 
4 Department of Oral Biology, University of Florida, Gainesville, FL, USA. 
5 Rheumatology Division, Universidade Federal de São Paulo, Escola Paulista 
de Medicina, Sao Paulo, Brazil. 6 Pontifícia Universidade católica de Goiás, 
Goiânia, Brazil. 7 Centraal Diagnostisch Laboratorium, MUMC, Maastricht, 
The Netherlands. 8 Department of Medical Microbiology and Immunology, 
University of Turku, Turku, Finland. 9 Rheumatology Laboratory, Department 
of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria. 
10 Medical Immunology, Laboratory Medicine, University Hospital Basel, 
Basel, Switzerland. 11 Department of Rheumatology and Clinical Immunol‑
ogy, Faculty of Medicine, School of Health Sciences, University of Thessaly, 
Larissa, Greece. 12 Servicio de Reumatología, Hospital Universitario Araba, 
Vitoria, Spain. 13 Department of Clinical Microbiology, Umeå University, Umeå, 
Sweden. 14 Department of Laboratory Diagnostics, University Hospital Centre 
Zagreb, Zagreb, Croatia. 15 Central Laboratory, East Tallin Central Hospital, 
Tallin, Estonia. 16 Department of Internal Medicine, Ghent University, Ghent, 
Belgium. 17 Department of Diagnostic Sciences, Ghent University, Ghent, 
Belgium. 18 Pôle de Pathologies Rhumatismales Et systémiques, Institut de 
Recherche Expérimentale et Clinique, Université Catholique de Louvain, 
Brussels, Belgium. 19 Department of Rheumatology, Cliniques Universitaires 
Saint‑Luc, Brussels, Belgium. 20 Department of Laboratory Medicine, GZA 
Hospitals, Antwerp, Belgium. 21 Department of Clinical Chemistry, University 
Hospital Liège, Liège, Belgium. 22 Department of Laboratory Medicine, AZ Sint‑
Jan Hospital Bruges‑Ostend, Bruges, Belgium. 23 Research Group Reproduc‑
tive Immunology and Implantation (REIM), Vrije Universiteit Brussel, Brussels, 
Belgium. 24 Division of Clinical Immunology and Rheumatology, Department 
of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia. 25 UK 
NEQAS Immunology, Northern General Hospital, Immunochemistry & Allergy, 
Sheffield, UK. 26 Department of Medicine, South Karelia Central Hospital, 
Lappeenranta, Finland. 27 Laboratory of the Mosaic of Autoimmunity, Saint 
Petersburg State University, Saint‑Petersburg, Russian Federation. 28 Zabludo‑
wicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Tel‑
Aviv University School of Medicine, Tel‑Hashomer, Tel Aviv, Israel. 29 Centro 
de Medicina, Laboratorial Germano de Sousa, Lisboa, Portugal. 30 Servicio 
de Inmunología, Hospital Universitario Marqués de Valdecilla, Santander, 
Cantabria, Spain. 31 UOC Microbiologia e Virologia, Presidio Ospedaliero San 
Carlo Borromeo, Milan, Italy. 32 Department of Laboratory Medicine, University 
Hospital Leuven, Leuven, Belgium. 
Received: 29 July 2020   Accepted: 29 August 2020
References
 1. Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatol‑
ogy Ad Hoc Committee on Immunologic Testing Guidelines. Evidence‑
based guidelines for the use of immunologic tests: antinuclear antibody 
testing. Arthritis Rheum. 2002;47:434–44.
 2. Meroni PL, Schur PH. ANA screening: an old test with new recommenda‑
tions. Ann Rheum Dis. 2010;69:1420–2.
 3. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey‑Goldman 
R, et al. 2019 European League Against Rheumatism/American College 
of Rheumatology classification criteria for systemic lupus erythematosus. 
Ann Rheum Dis. 2019;78:1151–9.
 4. Angeles‑Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker 
ML, et al. 2019 American College of Rheumatology/Arthritis Founda‑
tion guideline for the screening, monitoring, and treatment of juvenile 
idiopathic Arthritis‑Associated Uveitis. Arthritis Care Res (Hoboken). 
2019;71:703–16.
 5. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. 
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 
2008;48:169–76.
 6. Liver EAftSot. EASL clinical practice guidelines: autoimmune hepatitis. J 
Hepatol. 2015;63:971–1004.
 7. Mieli‑Vergani G, Vergani D. Autoimmune hepatitis. Nat rev Gastroenterol 
Hepatol. 2011;8:320–9.
 8. Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. 
Autoimm rev. 2014;13:441–4.
 9. Liver EAftSot. EASL clinical practice guidelines: management of choles‑
tatic liver diseases. J Hepatol. 2009;51:237–67.
 10. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio 
PLC, Fritzler MJ, et al. Clinical relevance of HEp‑2 indirect immunofluo‑
rescent patterns: the International Consensus on ANA patterns (ICAP) 
perspective. Ann Rheum Dis. 2019;78:879–89.
 11. Agmon‑Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, 
et al. International recommendations for the assessment of autoanti‑
bodies to cellular antigens referred to as anti‑nuclear antibodies. Ann 
Rheum Dis. 2014;73:17–23.
 12. Vergani D, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP, 
et al. Liver autoimmune serology: a consensus statement from the 
committee for autoimmune serology of the International Autoimmune 
Hepatitis Group. J Hepatol. 2004;41:677–83.
 13. Bossuyt X, Cooreman S, De Baere H, Verschueren P, Westhovens R, 
Blockmans D, et al. Detection of antinuclear antibodies by automated 
indirect immunofluorescence analysis. CCA. 2013;415:101–6.
 14. Schouwers S, Bonnet M, Verschueren P, Westhovens R, Blockmans 
D, Mariën G, et al. Value‑added reporting of antinuclear antibody 
testing by automated indirect immunofluorescence analysis. CCLM. 
2014;52:547–51.
 15. Oyaert M, Bossuyt X, Ravelingien I, Van Hoovels L. Added value of indi‑
rect immunofluorescence intensity of automated antinuclear antibody 
testing in a secondary hospital setting. CCLM. 2016;54:e63–e6666.
 16. Vulsteke JB, Willems P, Vander Cruyssen B, Vanderschueren S, West‑
hovens R, et al. Titre‑specific positive predictive value of antinuclear 
antibody patterns. Ann Rheum Dis. 2019. https ://doi.org/10.1136/
annrh uemdi s‑2019‑21624 5.
 17. Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo CW, Franc‑
escantonio PL, et al. Report of the first international consensus on 
standardized nomenclature of antinuclear antibody HEp‑2 cell patterns 
2014–2015. Front Immunol. 2015;6:412.
 18. Chan EK, Damoiseaux J, de Melo CW, Carballo OG, Conrad K, 
Francescantonio PL, et al. Report on the second International 
Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus. 
2016;25:797–804.
 19. Andrade LEC, Klotz W, Herold M, Conrad K, Rönnelid J, Fritzler MJ, et al. 
International consensus on antinuclear antibody patterns: definition of 
the AC‑29 pattern associated with antibodies to DNA topoisomerase I. 
CCLM. 2018;56:1783–8.
 20. Damoiseaux J, Bossuyt X, Broeders S, Hamann D, de Leeuw K, Limper M, 
et al. International Consensus on ANA Patterns (ICAP): inbedding in het 
Nederlandse taalgebied. Laboratoriumgeneeskunde. 2018;1:17–26.
 21. Van Hoovels L, Bossuyt X. Harmonisation of laboratory tests for rheumatic 
diseases: still a long way to go. Ann Rheum Dis. 2020;79:e5.
 22. Infantino M, Manfredi M, Soda P, Merone M, Afeltra A, Rigon A. ANA test‑
ing in ’real life’. Ann Rheum Dis. 2020;79:e3.
 23. Damoiseaux J, von Mühlen CA, La Garcia‑De Torre I, Carballo OG, de Melo 
Cruvinel W, Francescantonio PL, et al. International consensus on ANA 
patterns (ICAP): the bumpy road towards a consensus on reporting ANA 
results. Auto Immun Highlights. 2016;7:1.
 24. Peterson LK, Tebo AE, Wener MH, Copple SS, Fritzler MJ. Assessment of 
antinuclear antibodies by indirect immunofluorescent assay: report from 
a survey by the American Association of Medical Laboratory Immunolo‑
gists. CCLM. 2020. https ://doi.org/10.1515/cclm‑2019‑1262.
 25. Bizzaro N, Antico A, Platzgummer S, Tonutti E, Bassetti D, Pesente F, et al. 
Automated antinuclear immunofluorescence antibody screening: a 
comparative study of six computer‑aided diagnostic systems. Autoimm 
Rev. 2014;13:292–8.
 26. van Beers JJBC, Hahn M, Fraune J, Mallet K, Krause C, Hormann W, et al. 
Performance analysis of automated evaluation of antinuclear antibody 
indirect immunofluorescent tests in a routine setting. Auto Immun High‑
lights. 2018;9:8.
 27. Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled 
immunofluorescence pattern on HEp‑2 cells for the diagnosis of systemic 
autoimmune diseases. Clin Dev Immunol. 2012;2012:494356.
 28. Bizzaro N, Tonutti E, Villalta D. Recognizing the dense fine speckled/lens 
epithelium‑derived growth factor/p75 pattern on HEP‑2 cells: not an easy 
task! Arthritis Rheum. 2011;63:4036–7.
Page 12 of 12Van Hoovels et al. Autoimmun Highlights           (2020) 11:17 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 29. Bentow C, Fritzler MJ, Mummert E, Mahler M. Recognition of the dense 
fine speckled (DFS) pattern remains challenging: results from an interna‑
tional internet‑based survey. Auto Immun Highlights. 2016;7:8.
 30. Infantino M, Pregnolato F, Bentow C, Mahler M, Benucci M, Li Gobbi F, 
et al. Only monospecific anti‑DFS70 antibodies aid in the exclusion of 
antinuclear antibody associated rheumatic diseases: an Italian experi‑
ence. CCLM. 2019;57:1764–9.
 31. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero‑Diaz J, et al. 
The prevalence and determinants of anti‑DFS70 autoantibodies in an 
international inception cohort of systemic lupus erythematosus patients. 
Lupus. 2017;26:1051–9.
 32. Bonroy C, Schouwers S, Berth M, Stubbe M, Piette Y, Hoffman I, et al. The 
importance of detecting anti‑DFS70 in routine clinical practice: compari‑
son of different care settings. CCLM. 2018;56:1090–9.
 33. Infantino M, Shovman O, Pérez D, Grossi V, Manfredi M, Benucci M, et al. A 
better definition of the anti‑DFS70 antibody screening by IIF methods. J 
immunol Methods. 2018;461:110–6.
 34. Dellavance A, Baldo DC, Zheng B, Mora RA, Fritzler MJ, Hiepe F, et al. 
Establishment of an international autoantibody reference standard for 
human anti‑DFS70 antibodies: proof‑of‑concept study for a novel Mega‑
pool strategy by pooling individual specific sera. CCLM. 2019;57:1754–63.
 35. Vermeersch P, Bossuyt X. Prevalence and clinical significance of rare 
antinuclear antibody patterns. Autoimm rev. 2013;12:998–1003.
 36. Vermeersch P, Van den Bergh K, Blockmans D, Westhovens R, Bossuyt 
X. Anti‑Golgi autoantibodies are not clinically associated with systemic 
autoimmune diseases. Ann Rheum Dis. 2011;70:234–5.
 37. Van den Bergh K, Vercammen M, Regenass S, Derua R, Vermeersch P, 
Pokreisz P, et al. Betaine homocysteine methyl transferase 1, a novel 
auto‑antigen associated with anti‑Golgi immune reactivity. CCA. 
2012;413:105–8.
 38. Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Assay variation in the 
detection of antinuclear antibodies in the sera of patients with estab‑
lished SLE. Ann Rheum Dis. 2018;77:911–3.
 39. Mahler M. Lack of standardisation of ANA and implications for drug 
development and precision medicine. Ann Rheum Dis. 2019;78:e33.
 40. Van Hoovels L, Schouwers S, Van den Bremt S, Bossuyt X. Variation in anti‑
nuclear antibody detection by automated indirect immunofluorescence 
analysis. Ann Rheum Dis. 2018. https ://doi.org/10.1136/annrh eumdi 
s‑2018‑21354 3.
 41. Bogaert L, Van den Bremt S, Schouwers S, Bossuyt X, Van Hoovels L. Har‑
monizing by reducing inter‑run variability: performance evaluation of a 
quality assurance program for antinuclear antibody detection by indirect 
immunofluorescence. CCLM. 2019;57:990–8.
 42. Willems P, De Langhe E, Claessens J, Westhovens R, Van Hoeyveld E, 
Poesen K, et al. Screening for connective tissue disease‑associated anti‑
bodies by automated immunoassay. CCLM. 2018;56:909–18.
 43. Orme ME, Andalucia C, Sjölander S, Bossuyt X. A comparison of a fluo‑
rescence enzyme immunoassay versus indirect immunofluorescence 
for initial screening of connective tissue diseases: Systematic literature 
review and meta‑analysis of diagnostic test accuracy studies. Best Pract 
Res Clin Rheumatol. 2018;32:521–34.
 44. Claessens J, Belmondo T, De Langhe E, Westhovens R, Poesen K, Hüe S, 
et al. Solid phase assays versus automated indirect immunofluorescence 
for detection of antinuclear antibodies. Autoimm Rev. 2018;17:533–40.
 45. Bizzaro N, Brusca I, Previtali G, Alessio MG, Massimo D, Platzgummer 
S, et al. The association of solid‑phase assays to immunofluorescence 
increases the diagnostic accuracy for ANA screening in patients with 
autoimmune rheumatic diseases. Autoimmun Rev. 2018;17:541–7.
 46. Meroni PL, Chan EK, Damoiseaux J, Andrade LEC, Bossuyt X, Conrad K, 
et al. Unending story of the indirect immunofluorescence assay on HEp‑2 
cells: old problems and new solutions? Ann Rheum Dis. 2019;78:e46.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
